Drug Database
Back to search

Japan· JP-3999042F1025

アプレミラスト

A apremilast product containing アプレミラスト, registered in Japan by アムジェン, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

On Japan’s NHI price listATC L04AA32

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedアプレミラストATCL04AA32REGISTER NO.JP-3999042F1025PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about アプレミラストAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Apremilast is registered in 18 of 19 countries.

Countries holding a registration under ATC L04AA32 (apremilast), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 10 of them publish a price we can compare per daily dose
Search apremilast products by name

Apremilast · ATC L04AA32

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apremilast costs, country by country.

Normalised to the WHO defined daily dose (60 mg), the median price runs from $13.92 in Switzerland to $51.51 in Italy — a ×3.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Apremilast · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • IT Italy$51.51
  • CZ Czechia$51.22
  • FR France$22.59
  • CH Switzerland$13.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
アプレミラスト
Manufacturer
アムジェン
Country
Japan (JP)
ATC code
L04AA32
ATC class
Apremilast
Defined daily dose
60 mg, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for apremilast.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check apremilast against other medicinesHow interaction checks work

Apremilast · interactions on record

82 records

  • 11 severe
  • 69 moderate
  • 2 minor

Most severe, free to view

  • RifampicinJ04AB02severe
  • MitotaneL01XX23severe
  • EnzalutamideL02BB04severe
  • ApalutamideL02BB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under L04AA32

Apremilast, as other registers publish it.

All apremilast products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b3741ba4-d783-4229-869b-7eb3fe5cd241
GET /v1/drugs/b3741ba4-d783-4229-869b-7eb3fe5cd241?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１０ｍｇ１錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "3999042F1025",
  "category": "内用薬",
  "price_yen": 284.4,
  "generic_name": "アプレミラスト",
  "product_name_jp": null,
  "therapeutic_class": "3999",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about apremilast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console